AstraZeneca Pharma drops as company skips dividend on poor financials

Image
Capital Market
Last Updated : May 22 2013 | 12:30 PM IST

The announcement was made after market hours on Tuesday, 21 May 2013.

Meanwhile, the BSE Sensex was up 68.64 points, or 0.34%, to 20,180.25.

On BSE, 8,793 shares were traded in the counter as against an average daily volume of 37,714 shares in the past one quarter.

The stock hit a high of Rs 799.35 and a low of Rs 766.65 so far during the day. The stock had hit a 52-week high of Rs 2,019.90 on 29 May 2012. The stock had hit a 52-week low of Rs 595 on 26 March 2013.

The stock had outperformed the market over the past one month till 21 May 2013, rising 11.71% compared with the Sensex's 5.76% rise. The scrip, however, underperformed the market in past one quarter, sliding 28.63% as against Sensex's 4.07% rise.

The small-cap company has an equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India's board of directors at its meeting held on 21 May 2013, said it has not recommended any dividend on equity shares for the year ended 31 March 2013 in view of absence of profits for the year ended 31 March 2013 and to conserve resources for future growth. Earlier, the company had declared equity dividend for all the years since atleast 2000.

Astrazeneca Pharma India reported net loss of Rs 18.58 crore in Q4 March 2013 as against net loss of Rs 33.01 crore in Q4 March 2012. Net sales rose 3.4% to Rs 94.85 crore in Q4 March 2013 over Q4 March 2012.

AstraZeneca Pharma India is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. AstraZeneca Pharma India is involved in both the manufacturing and marketing of medicines.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 22 2013 | 11:15 AM IST

Next Story